R Ertas1, K Ozyurt1, M Atasoy1, T Hawro2, M Maurer2. 1. Kayseri Education and Research Hospital Dermatology Clinic, Kayseri, Turkey. 2. Department of Dermatology and Allergy, Dermatological Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Abstract
BACKGROUND: Omalizumab is an effective and well-tolerated treatment for chronic spontaneous urticaria (CSU). Markers and predictors of response are largely unknown, but needed to optimize omalizumab treatment. Omalizumab targets IgE, and IgE levels may be linked to the effects of treatment. We evaluated whether response rates to treatment with omalizumab in patients with CSU are linked to their baseline IgE levels, their IgE levels after omalizumab treatment, and the ratio of on treatment IgE and baseline IgE levels. METHODS: Chronic spontaneous urticaria (CSU) patients (n = 113) were treated with omalizumab 300 mg/4 weeks for 12 weeks, when their treatment responses, that is, no, partial, or complete response, were assessed by use of the urticaria activity score, physician and patient visual analog scale, and treatment effectiveness score. Total IgE levels were measured before treatment (bIgE) with omalizumab and 4 weeks thereafter (w4IgE). RESULTS: Nonresponders to omalizumab had significantly lower bIgE levels (17.9, 17.0-55.0 IU/mL) than partial responders (82.0, 46.2-126.5 IU/mL, P = .008) and complete responders (73.7, 19.45-153.8 IU/mL, P = .032). Nonresponders also had lower w4IgE levels and lower ratios of w4IgE/bIgE levels than partial and complete responders (P < .001). Nonresponse to omalizumab was best predicted by patients' w4IgE/bIgE ratios, significantly better than by bIgE levels (P = .016). CONCLUSIONS: In CSU, total IgE levels and their change predict the response to treatment with omalizumab. The assessment of pre- and post-treatment IgE levels and their ratio may help to improve the management of CSU in patients who require omalizumab treatment.
BACKGROUND:Omalizumab is an effective and well-tolerated treatment for chronic spontaneous urticaria (CSU). Markers and predictors of response are largely unknown, but needed to optimize omalizumab treatment. Omalizumab targets IgE, and IgE levels may be linked to the effects of treatment. We evaluated whether response rates to treatment with omalizumab in patients with CSU are linked to their baseline IgE levels, their IgE levels after omalizumab treatment, and the ratio of on treatment IgE and baseline IgE levels. METHODS: Chronic spontaneous urticaria (CSU) patients (n = 113) were treated with omalizumab 300 mg/4 weeks for 12 weeks, when their treatment responses, that is, no, partial, or complete response, were assessed by use of the urticaria activity score, physician and patient visual analog scale, and treatment effectiveness score. Total IgE levels were measured before treatment (bIgE) with omalizumab and 4 weeks thereafter (w4IgE). RESULTS: Nonresponders to omalizumab had significantly lower bIgE levels (17.9, 17.0-55.0 IU/mL) than partial responders (82.0, 46.2-126.5 IU/mL, P = .008) and complete responders (73.7, 19.45-153.8 IU/mL, P = .032). Nonresponders also had lower w4IgE levels and lower ratios of w4IgE/bIgE levels than partial and complete responders (P < .001). Nonresponse to omalizumab was best predicted by patients' w4IgE/bIgE ratios, significantly better than by bIgE levels (P = .016). CONCLUSIONS: In CSU, total IgE levels and their change predict the response to treatment with omalizumab. The assessment of pre- and post-treatment IgE levels and their ratio may help to improve the management of CSU in patients who require omalizumab treatment.
Authors: Marcus Maurer; Kilian Eyerich; Stefanie Eyerich; Marta Ferrer; Jan Gutermuth; Karin Hartmann; Thilo Jakob; Alexander Kapp; Pavel Kolkhir; Désirée Larenas-Linnemann; Hae-Sim Park; Gunnar Pejler; Mario Sánchez-Borges; Knut Schäkel; Dagmar Simon; Hans-Uwe Simon; Karsten Weller; Torsten Zuberbier; Martin Metz Journal: Int Arch Allergy Immunol Date: 2020-03-30 Impact factor: 2.749
Authors: Désirée E S Larenas-Linnemann; Claudio A S Parisi; Carla Ritchie; Ricardo Cardona-Villa; Ivan Cherrez-Ojeda; Annia Cherrez; Luis Felipe Ensina; Elizabeth Garcia; Iris V Medina; Mónica Rodríguez-González; Jorge Mario Sánchez Caraballo Journal: Curr Allergy Asthma Rep Date: 2018-05-09 Impact factor: 4.806
Authors: Kirti J Johal; Kristin L Chichester; Eric T Oliver; Kelly C Devine; Anja P Bieneman; John T Schroeder; Donald W MacGlashan; Sarbjit S Saini Journal: J Allergy Clin Immunol Date: 2021-03-10 Impact factor: 14.290
Authors: D M Barrios; G S Phillips; A N Geisler; S R Trelles; A Markova; S J Noor; E A Quigley; H C Haliasos; A P Moy; A M Schram; J Bromberg; S A Funt; M H Voss; A Drilon; M D Hellmann; E A Comen; S Narala; A B Patel; M Wetzel; J Y Jung; D Y M Leung; M E Lacouture Journal: Ann Oncol Date: 2021-03-03 Impact factor: 51.769